
Seer, Inc. — Investor Relations & Filings
Seer, Inc. is a life sciences company that develops and commercializes products to advance proteomics research. The company's core offering is the Proteograph Product Suite, an integrated platform designed to provide deep, unbiased, and large-scale access to the proteome. Utilizing proprietary engineered nanoparticles, Seer's technology enables researchers to analyze complex biological samples with high throughput, speed, and reproducibility. This approach facilitates the comprehensive detection of proteins, including those at low abundance that are critical for understanding disease and health states. The platform is complemented by the Proteograph Analysis Suite, a software solution for data analysis and biomarker discovery. Seer aims to empower the scientific community with tools to overcome technological barriers in proteomics, accelerating insights in precision medicine and human biology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | |
| 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | |
| 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 39212809 | 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | ||
| 38584983 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | ||
| 36141962 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | ||
| 34439529 | 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | ||
| 34439493 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | ||
| 32897348 | 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English | ||
| 32897347 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897346 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897344 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 32897345 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 31497902 | 4 Filing | 2026-02-05 | English | ||
| 31497881 | 4 Filing | 2026-02-05 | English | ||
|
2025
3 filings
| |||||
| 13086780 | 8-K | 2025-12-12 | English | ||
| 13086781 | Director's Dealing 2025 | 2025-12-12 | English | ||
| 13086784 | Director's Dealing 2025 | 2025-12-12 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ectin Research AB
Pharmaceutical company developing novel oncology treatments…
|
ECTIN B | SE | Professional, scientific and te… |
|
EdgeLab S.p.A.
Designs and manufactures marine and underwater solutions, i…
|
ELB | IT | Professional, scientific and te… |
|
Editas Medicine, Inc.
A clinical-stage genome editing company developing CRISPR m…
|
EDIT | US | Professional, scientific and te… |
|
EGF Theramed Health Corp.
Developing psychedelic drugs for mental health, diagnostic …
|
TMED | CA | Professional, scientific and te… |
|
Eikon Therapeutics, Inc.
Integrates live-cell imaging and computing to discover ther…
|
EIKN | US | Professional, scientific and te… |
|
Eledon Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for organ and a…
|
ELDN | US | Professional, scientific and te… |
|
Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and …
|
ELIC | SE | Professional, scientific and te… |
|
Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immun…
|
ELTX | US | Professional, scientific and te… |
|
EMYRIA LIMITED
Clinical-stage biotech developing mental health and neurolo…
|
EMD | AU | Professional, scientific and te… |
|
Energenesis Biomedical CO.,LTD.
Develops small molecule drugs for cellular energy regulatio…
|
6657 | TW | Professional, scientific and te… |
Seer, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34036/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34036 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34036 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34036 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34036}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Seer, Inc. (id: 34036)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.